Michael Mollerus
Lawyers
Filters
S&P Global and CME Group $3.1 billion sale of OSTTRA to KKR
We are advising S&P Global on the transaction
Paychex $4.2 billion senior notes offering
We advised Paychex on its investment-grade notes offering
Insulet $450 million senior notes offering
The high-yield notes are due 2033
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
Endo divestiture of International Pharmaceuticals business
We are advising Endo on the transaction
Emerson €1 billion and $500 million notes offering
The investment-grade debt consists of three tranches of notes
Venture Global $1.75 billion IPO
We advised Venture Global on its IPO and NYSE listing
Emerson $7.2 billion acquisition of remaining outstanding shares of AspenTech
We are advising Emerson on its acquisition
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition